Loading cancer entity…
Loading cancer entity…
Clinical trials
36 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT01391962 | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2026 |
| clinicaltrials |
| NCT00942877 | Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02636725 | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 33 | Jonathan Trent, MD, PhDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00401388 | A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas | completed | Phase 2 | 72 | AEterna ZentarisINDUSTRY | 0 | Mar 7, 2018 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials